Evidence for anti-vascular endothelial growth factor treatment of diabetic macular oedema

Francesco Bandello, Umberto De Benedetto, Karl Anders Knutsson, Maurizio Battaglia Parodi, Maria Lucia Cascavilla, Pierluigi Iacono

Research output: Contribution to journalArticle

Abstract

Diabetic macular oedema (DME) represents the most common cause of vision loss in patients affected by diabetes mellitus. Diabetic retinopathy has a significant impact on public health and the quality of life of many patients and thus requires serious consideration. The first line of treatment remains the management of systemic risk factors but this is often insufficient in controlling DME and currently, laser retinal photocoagulation is considered the standard of care. However, laser treatment reduces the risk of moderate visual loss by approximately 50 % without guaranteeing remarkable effects on visual improvement. For these reasons, new approaches in the treatment of DME have been considered, in particular the employment of anti-vascular endothelial growth factor (VEGF) drugs. VEGF is a pluripotent growth factor that functions as a vasopermeability factor and an endothelial cell mitogen and thereby represents an appealing candidate as a therapeutic target for the treatment of DME. The goal of this article is to present the evidence behind the use of anti-VEGF drugs in the treatment of DME.

Original languageEnglish
Pages (from-to)36-41
Number of pages6
JournalEuropean Endocrinology
Volume8
Issue number1
Publication statusPublished - 2012

Keywords

  • Anti-vascular endothelial growth factor
  • Anti-vascular endothelial growth factor Trap-Eye
  • Bevacizumab
  • Bevasiranib
  • Diabetic macular oedema
  • Pegaptanib
  • Ranibizumab
  • Rapamycin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems

Fingerprint Dive into the research topics of 'Evidence for anti-vascular endothelial growth factor treatment of diabetic macular oedema'. Together they form a unique fingerprint.

  • Cite this

    Bandello, F., De Benedetto, U., Knutsson, K. A., Parodi, M. B., Cascavilla, M. L., & Iacono, P. (2012). Evidence for anti-vascular endothelial growth factor treatment of diabetic macular oedema. European Endocrinology, 8(1), 36-41.